Slide 1: Vext Reports Q1 2026 Financial Results; Adjusted EBITDA Up Sequentially to $3.6 Million
Vext Reports Q1 2026 Financial Results; Adjusted EBITDA Up 73% Sequentially to $3.6 Million as Ohio Platform Scales • Revenue of $12.2 million, up 5.2% year-over-year; gross profit more than doubled to $5.5 million (45.4% margin), and net loss narrowed 73.2% to $(0.9) million. • Operating cash flow
Slide 2: Q1 2026 Financial Results Conference Call
of Arizona that has maintained economic viability: two dispensaries, light manufacturing, and the flexibility to source and price competitively. Between an Ohio platform that's scaling, and an Arizona business now right-sized for the market, we believe the business is well positioned to continue gen
Slide 3: Uncertain Tax Position and Income Tax Payable
made to the March 31, 2026 financial statements. The Company will evaluate the impact, if any, in future reporting periods. For additional details, please refer to the Company’s condensed consolidated interim financial statements (including the notes thereto) and MD&A filed on SEDAR+. Non-IFRS Finan
Slide 4: Adjusted EBITDA Reconciliation
exchange and acquisition related costs, if applicable. The Company defines “Adjusted EBITDA Margin” as Adjusted EBITDA divided by Sales. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should
Slide 5: Forward Looking Statements
and connect with Vext on Twitter/X and LinkedIn. Forward Looking Statements Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext’s periodic filings with Canadian securit
Slide 6: For further information
844-211-3725 For further information: Jonathan Ross, Vext Investor Relations jon.ross@loderockadvisors.com 416-244-9851 SOURCE: Vext Science, Inc. 6